Innovative Technology Stilla Technologies offers cutting-edge digital PCR solutions with their unique Multiplex Crystal Digital PCR technology and the naica system, providing high sensitivity and multiplexing capabilities that appeal to advanced genomics laboratories and clinical research facilities.

Expanding Market Reach Following strategic partnerships with companies like Source Bioscience and distribution agreements with Avantor, Stilla is actively expanding its presence in key markets such as the UK and US, opening avenues to engage with regional research institutions and healthcare providers.

Recent Acquisition Bio-Rad Laboratories' acquisition of Stilla Technologies for $8.49 billion signals strong industry validation and potential for increased distribution and sales opportunities through Bio-Rad’s extensive global network.

Product Expansion The launch of new digital PCR assays for liquid biopsy applications and awards like the Red Dot Design Award enhance Stilla’s product portfolio, attracting top-tier research institutions and biotech companies seeking innovative and reliable testing solutions.

Funding & Growth With recent Series C funding of $26.5 million and revenues between $1 million and $10 million, Stilla is positioned to scale its operations and sales efforts, especially by targeting biotech, pharma, and hospital laboratories engaged in molecular diagnostics and personalized medicine.